Myomo (MYO) investor relations material

Strategic positioning and market opportunity

• Established a new product category with the MyoPro myoelectric orthosis, securing first-mover advantage in a large and expanding market with strong competitive positioning.

• CMS reimbursement and new payer contracts are expanding patient access, with growing revenues from recurring patient sources and an attractive margin profile.

• The total addressable market is estimated to double with Medicare Part B reimbursement, targeting 3.8 million stroke survivors with upper extremity impairment in the U.S.

Product innovation and clinical evidence

• MyoPro is the only device that restores arm function using advanced sensor technology and proprietary control algorithms, amplifying EMG signals to enable voluntary movement.

• The device is lightweight, portable, and designed for use at home, work, and school, addressing unmet needs not met by current treatments.

• Clinical studies and systematic reviews show statistically significant and clinically meaningful improvements in upper extremity function for users, with ongoing randomized controlled trials.

• 35 patents are valid through 2042, with additional patents pending.

Insurance reimbursement and market access

• HCPCS codes L8701 and L8702 provide lump sum reimbursement, with updated fees effective January 2026 ($34,970 and $68,802 respectively).

• Contracts with commercial payers now cover over 80 million lives, with multi-state contracts in progress and more than 100 VA medical centers ordering MyoPro.

• Covered lives are projected to reach 158 million by July 2026, pending completion of new contracts.